Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$272.18 USD

272.18
308,831

-4.62 (-1.67%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $272.29 +0.11 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Cerner (CERN) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results benefit from gains across four of its business units.

Zacks Equity Research

LHC Group (LHCG) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Despite the weak bottom-line performance, LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health admissions.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.

Zacks Equity Research

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down

by Zacks Equity Research

Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.

Zacks Equity Research

Medtronic's (MDT) Q3 Earnings Beat, Revenues Lag Estimates

by Zacks Equity Research

Medtronic (MDT) registers organic growth in the Cardiovascular, Neuroscience and Diabetes segments in Q3.

Zacks Equity Research

Shockwave Medical (SWAV) Gains 3.2% Post Q4 Earnings Beat

by Zacks Equity Research

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and expansion in gross margin.

Zacks Equity Research

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) robust Q4 results demonstrate its segmental strength.

Zacks Equity Research

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.

Zacks Equity Research

West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.

Zacks Equity Research

Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.

Zacks Equity Research

Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.

Zacks Equity Research

Wall Street Analysts Think Bio-Rad (BIO) Could Surge 42%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Ecolab (ECL) Q4 Earnings & Revenues Beat Mark, Margins Down

by Zacks Equity Research

Ecolab's (ECL) robust performance across most of its segments drives its Q4 sales despite business challenges.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Q4 Earnings Top Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH

by Urmimala Biswas

Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.

Zacks Equity Research

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.

Zacks Equity Research

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist

by Zacks Equity Research

Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.

Zacks Equity Research

Has Bio-Rad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Zacks Equity Research

Philips (PHG) to Buy Vesper Medical, Expand Vascular Portfolio

by Zacks Equity Research

Philips (PHG) is set to acquire Vesper Medical to strengthen its vascular devices portfolio and customer base.

Zacks Equity Research

Is Bio-Rad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.